The diagnostic utility of EZH2 H-score and Ki-67 index in non-invasive breast apocrine lesions.


Journal

Pathology, research and practice
ISSN: 1618-0631
Titre abrégé: Pathol Res Pract
Pays: Germany
ID NLM: 7806109

Informations de publication

Date de publication:
Sep 2020
Historique:
received: 24 03 2020
revised: 14 05 2020
accepted: 31 05 2020
entrez: 23 8 2020
pubmed: 23 8 2020
medline: 2 7 2021
Statut: ppublish

Résumé

In diagnostic breast pathology, there is no reliable applicable immunostain to help discern atypical and in situ apocrine lesions from benign apocrine tissue. At present, the diagnosis of non-invasive apocrine lesions remains challenging with current diagnoses rendered based on discrete morphologic characteristics on conventional hematoxylin and eosin staining. Interobserver variability is significant even among subspecialists partly due to lack of adjuvant diagnostic immunohistochemical stains. Herein, we set to elucidate the potential utility of EZH2 and Ki-67 immunostains as tangible tools in non-invasive apocrine proliferations. A cohort of apocrine breast lesions [Benign apocrine hyperplasia (BAH), n = 10; Atypical apocrine hyperplasia (AAH), n = 16; Apocrine ductal carcinoma in situ (ADCIS), n = 12] were subjected to EZH2 immunostaining and analyzed via H-scoring of nuclear expression. Mean H-scores for EZH2 progressively increased from BAH (23.5), to AAH (47.4) and ADCIS (196.4), and showed a significant difference utilizing the Kruskal-Wallis test (p < 0.0001). Further interrogation of Ki-67 demonstrated incremental expression from BAH to AAH and ADCIS at 1.6 %, 4.7 % and 24.7 %, respectively (p < 0.0001, Kruskal-Wallis test), suggesting an association with increased proliferation. Our results demonstrate that a combination of EZH2 and Ki-67 immunostaining may be employed in differentiating among challenging apocrine breast lesions and suggest a putative diagnostic utility for EZH2 and Ki-67 in non-invasive apocrine breast lesions.

Identifiants

pubmed: 32825929
pii: S0344-0338(20)30876-1
doi: 10.1016/j.prp.2020.153041
pii:
doi:

Substances chimiques

Biomarkers, Tumor 0
Ki-67 Antigen 0
EZH2 protein, human EC 2.1.1.43
Enhancer of Zeste Homolog 2 Protein EC 2.1.1.43

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

153041

Informations de copyright

Copyright © 2020 Elsevier GmbH. All rights reserved.

Auteurs

Theodore Vougiouklakis (T)

Department of Pathology, New York University Langone Health, New York, NY, USA.

Brendan J Belovarac (BJ)

Department of Pathology, New York University Langone Health, New York, NY, USA.

Andrew Lytle (A)

Department of Pathology, New York University Langone Health, New York, NY, USA.

Luis Chiriboga (L)

Department of Pathology, New York University Langone Health, New York, NY, USA.

Ugur Ozerdem (U)

Department of Pathology, New York University Langone Health, New York, NY, USA. Electronic address: ugur.ozerdem@nyumc.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH